Women’s Health Market Size To Reach $68.53 Billion By 2030

Women's Health Market Growth & Trends

The global women’s health market size is expected to reach USD 68.53 billion by 2030, registering a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The introduction of innovative novel products and the presence of a strong pipeline of women’s health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.

For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.

For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.

For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women’s health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.

 Request a free sample copy or view report summary: Women’s Health Market Report

Women's Health Market Report Highlights

• The contraceptives segment held the highest revenue share of more than 35.07% of the global revenue in 2024, spurred by rising awareness of family planning and ongoing technological advancements in contraceptive methods.

• Hormonal therapies segment led the market in 2024 and is expected to grow at fastest growth rate over the forecast period.

• The others (below 50 years) segment dominated the market in 2024 and is expected to sustain the position for the forecast period. Women aged below 50 years are more likely to face issues associated with fertility, such as endometriosis, hormonal infertility, and polycystic ovary syndrome.

• The North America women’s health market dominated the global market with a share of 43.04% in 2024.

Women's Health Market Segmentation

Grand View Research has segmented the global women's health market on the basis of application, drug class, age, and region:

Women’s Health Application Outlook (Revenue, USD Million, 2018 - 2030)

• Hormonal Infertility

• Contraceptives

• Postmenopausal Osteoporosis

• Endometriosis & Uterine Fibroids

• Menopause

• Polycystic Ovary Syndrome (PCOS)

Women’s Health Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Hormonal Therapies

• Bone Health Agents

• Fertility Agents

• GnRH Modulators

• Pain and Symptom Management

• Metabolic Agents

• Others

Women’s Health Age Outlook (Revenue, USD Million, 2018 - 2030)

• 50 years and above

  • Postmenopausal Osteoporosis

  • Endometriosis & Uterine Fibroids

  • Menopause

  • Others

• Others

Women’s Health Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Women's Health Market

• AbbVie, Inc.

• Bayer AG

• Organon & Co.

• Pfizer, Inc.

• Theramex

• Agile Therapeutics

• Amgen, Inc.

• Apothecus Pharmaceutical Corp.

• Blairex Laboratories, Inc.

• Ferring